Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival

Watad, A orcid.org/0000-0002-1404-8027, McGonagle, D, Bragazzi, NL et al. (5 more authors) (2019) Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. OncoImmunology, 8 (6). e1588084. ISSN 2162-4011

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019, Taylor & Francis Group, LLC. This is an author produced version of a paper published in OncoImmunology. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: Systemic sclerosis; scleroderma; malignancy; cancer; autoantibodies; autoimmune diseases
Dates:
  • Published: 3 June 2019
  • Accepted: 25 February 2019
  • Published (online): 24 March 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Experimental Musculoskeletal Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 12 Jun 2019 15:38
Last Modified: 24 Mar 2020 01:38
Status: Published
Publisher: Taylor & Francis
Identification Number: https://doi.org/10.1080/2162402X.2019.1588084
Related URLs:

Share / Export

Statistics